Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VX-659 triple combination therapy in adults with cystic fibrosis
2016-003585-11Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bamocaftor, tezacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Jul 2017; status: completed.
02
Drugs
bamocaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-003585-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003585-11.